ClinicalTrials.Veeva

Menu

Dexmedetomidine Infusion During Laparoscopic Adrenalectomy

Yonsei University logo

Yonsei University

Status

Completed

Conditions

Pheochromocytoma

Treatments

Drug: dexmedetomidine
Drug: 0.9% normal saline

Study type

Interventional

Funder types

Other

Identifiers

NCT06037135
4-2012-0577

Details and patient eligibility

About

The investigators planned this study to investigate the effects of dexmedetomidine administration on intraoperative hemodynamic stability in patients with pheochromocytoma.

Enrollment

40 patients

Sex

All

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. ages of 20 and 70
  2. American Society of Anesthesiologists(ASA) physical status classification I to III,
  3. planned laparoscopic adrenalectomy for pheochromocytoma.

Exclusion criteria

  1. emergency operation,
  2. re-operation,
  3. combined surgery with other departments,
  4. body mass index (BMI) >32 kg/m2,
  5. history of arrhythmias (especially AV nodal block) and ventricular conduction abnormalities,
  6. uncontrolled hypertension (diastolic blood pressure >110mmHg)
  7. bradycardia (heart rate < 40 beats per minute),
  8. history of heart failure, hepatic and/or renal failure,
  9. history of cerebrovascular disease (cerebral hemorrhage, cerebral ischemia),
  10. history of beta-blocker therapy, 10) history of uncontrolled psychiatric disease.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

40 participants in 2 patient groups

dexmedetomidine group
Experimental group
Description:
In the dexmedetomidine group, dexmedetomidine is administered at a rate of 0.5 μg/kg/h immediately after anesthesia induction and continued until the completion of the surgery.
Treatment:
Drug: dexmedetomidine
Control group
Active Comparator group
Description:
In the control group, a 0.9% normal saline infusion is initiated at the same rate immediately after anesthesia induction and continued until the end of the operation.
Treatment:
Drug: 0.9% normal saline

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems